← Back to Search

Antiplatelet Agent

ASA and Celecoxib for Rheumatoid Arthritis

Phase 4
Recruiting
Research Sponsored by Inova Health Care Services
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Study Summary

The objectives of this single site, randomized, crossover study is to evaluate the pharmacodynamic interactions between aspirin, NSAIDs and Coxibs with respect to platelet function, biomarkers of inflammation and endothelial function.

Eligible Conditions
  • Rheumatoid Arthritis
  • Cardiovascular Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Platelet aggregation
Secondary outcome measures
Endothelial function by EndoPAT
Oxidized LDL
Serum TxB2
+4 more

Trial Design

2Treatment groups
Active Control
Group I: ASA and CelecoxibActive Control2 Interventions
Take celecoxib 200mg capsule twice a day and aspirin 81mg tablet once a day for 4 weeks (after completion of the run-in period)
Group II: ASA and NaproxenActive Control2 Interventions
Take naproxen sodium 550mg tablet twice a day and aspirin 81mg tablet once a day (after completion of the run-in period)

Find a Location

Who is running the clinical trial?

Inova Health Care ServicesLead Sponsor
69 Previous Clinical Trials
22,225 Total Patients Enrolled
Kevin Bliden, BS, MBAStudy DirectorInova Health Care Services

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~5 spots leftby May 2025